TNG Digital and EPOS Launch EPOS360 and EPOS360 BlueTap in Malaysia to Help Local SMEs Grow with AI and Unique Payment Capabilities
15.1.2026 11:23:00 CET | Business Wire | Press release
EPOS360, an industry-first all-in-one digital and payments solution, launches as a mini-programme within TNG eWallet, enabling Malaysian SMEs to easily access AI-powered growth tools to engage over 25 million TNG eWallet usersTNG Digital introduces EPOS360 BlueTap, Malaysia’s first tap-to-pay experience using TNG eWalletThrough EPOS, Ant International will make significant strides to empower SME digitalisation, leading the charge for its SME inclusion and growth strategy
TNG Digital Sdn. Bhd. (“TNG Digital”), the operator of Malaysia’s leading digital financial services and lifestyle app, TNG eWallet, and EPOS, the all-in-one SME transformation platform of Ant International, have jointly announced the launch of EPOS360 in Malaysia, with a suite of AI-powered growth tools and unique payment capabilities to support the digitalisation of Malaysian businesses, particularly SMEs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115763131/en/

[From left] Mr. Sarveswaran Raja Gopal, Chief Commercial Officer of TNG Digital; Mr. Alan Ni, Chief Executive Officer of TNG Digital; [middle] En. Anuar Fariz Fadzil, Chief Executive Officer of Malaysia Digital Economy Corporation (MDEC); Mr. Gary Liu, Chief Executive Officer of Antom and Senior Vice President of Ant International; and Mr. Alan Wang, Chief Executive Officer of EPOS and Vice President of Ant International, at the launch of EPOS360 and EPOS360 BlueTap, initiatives designed to support Malaysian SMEs with AI-powered tools and innovative payment capabilities.
CEO of MDEC, Anuar Fariz Fadzil said, "The launch marks an important milestone in Malaysia’s business digitalisation journey, ensuring that businesses of all sizes have access to affordable, relevant and easy-to-adopt digital tools to scale sustainability and compete more effectively. By embedding AI-powered business tools and innovative payment capabilities into a platform that millions of Malaysians already use, this initiative enables digital entrepreneurs to participate more meaningfully in the digital economy and supports Malaysia’s aspiration to become an AI Nation by 2030”.
He added that as MDEC celebrates its 30th anniversary this year of championing Malaysia’s digital economy, initiatives like this directly support the nation’s agenda by ensuring businesses remain resilient, competitive, and future-ready.
EPOS360 launches as a mini-programme in TNG eWallet, giving Malaysian SMEs direct access to AI-powered tools, integrated payments, and marketing capabilities in one place. Through TNG eWallet features such as Near Me vouchers, merchants can reach over 25 million users, while managing key business functions seamlessly within a single solution.
Alan Ni, Chief Executive Officer of TNG Digital, said, “SMEs are at the heart of Malaysia’s economy. Our role at TNG Digital is to remove barriers and make growth easier. By bringing EPOS360 into TNG eWallet, we are giving businesses simple, trusted tools to reach more customers, run their businesses better, and grow within an ecosystem that millions of Malaysians use every day.”
Brand new payment experience led by TNG eWallet
As part of EPOS360, TNG Digital and EPOS are introducing EPOS360 BlueTap, a smart over-the-counter device that supports multiple payment methods in one terminal.
For the first time in Malaysia, via BlueTap, consumers can tap-to-pay with TNG eWallet, which also supports DuitNow QR, major eWallets, and soon, card payments. This helps merchants through:
- Clear audio payment confirmation at the point of sale, giving businesses immediate assurance that a transaction is successful, reducing missed payments or manual checks, particularly during peak hours
- Integration with TNG eWallet ecosystem, enabling access to point-of-sale features and transaction insights for a simpler and more reliable checkout experience while supporting business growth
- Supporting trusted acceptance across banks and major eWallets in one device, accommodating additional payment types over time without frequent hardware changes
SME digitalisation at scale
Malaysian SMEs can access EPOS360 solutions directly within the TNG eWallet they know and trust, tapping on its significant digital user base, and engage them using a range of AI-powered solutions, which will be progressively introduced, to support every stage of the SME journey:
- End-to-end digitalisation: From online set up, with AI Copilot easily creating online menus based on photos or descriptions, to marketing services, to deploying across digital channels like in-app or Google Maps.
- Reach and engage more customers: Create customised campaigns, vouchers and marketing materials via AI, and simultaneously launch across:
- In-app – by connecting with TNG eWallet in-app marketing services like the Near Me feature, SMEs can directly engage millions of consumers with relevant and timely promotions
- Digital – on multiple social media channels, and online storefront including Google Maps
- Offline – on BlueTap devices to immediately reach customers
- Scale: Access business insights and customer support that enables business owners to optimise their operations, customer engagement and troubleshooting.
Alan Wang, CEO of EPOS and Vice President of Ant International, said: “SMEs are the heart of our communities, and yet they face very real challenges in an increasingly competitive environment. Digitalisation is no longer a nice to have, and we believe that by putting the right technology into the hands of SMEs, we can empower them to unlock new and exciting opportunities. We’re excited to partner with TNG Digital, Malaysia’s biggest mobile ecosystem to bring this vision to reality, and jointly accelerate the growth and transformation of local SMEs. Moving forward, Ant International, through EPOS, will significantly accelerate its strategy to drive SME digitalisation in Southeast Asia and beyond.”
EPOS360 is an industry-first solution that brings together AI-powered solutions, enhanced payment capabilities, financial services and more into one platform, making it easy for SMEs to transform and grow in the digital era. It has launched in Malaysia, and soon in Singapore.
This initiative is supported by the Malaysia Digital Economy Corporation (MDEC) as part of its ongoing efforts to advance Malaysia’s digital economy.
Merchants can find out more about EPOS360 and EPOS360 BlueTap, and how it supports daily operations at https://www.touchngo.com.my/merchant/epos3X`60-bluetap/
About TNG Digital Sdn Bhd
TNG Digital Sdn Bhd, the operator of TNG eWallet, is Malaysia’s leading digital financial services and lifestyle app, with over 25 million verified users and more than 2 million merchant touchpoints nationwide. Established in 2017, the company has grown into a multi-service platform offering access to investments, lending, credit, remittance, insurance, and other lifestyle services through its platform and partnerships.
Beyond payments, TNG eWallet connects users to the global economy with international transactions in over 50 countries and enables tourists to enjoy a fully digital experience in Malaysia. Beyond consumers, the company supports micro and small businesses through the TNG Digital Business Account and merchant solutions that help them grow, reach more customers, and strengthen financial capabilities.
TNG Digital is committed to advancing financial inclusion and expanding access to the digital economy for individuals and businesses alike. For more information, please visit www.touchngo.com.my/ewallet
About Ant International
With headquarters in Singapore and main operations across Asia, Europe, the Middle East and Latin America, Ant International is a leading global digital payment, digitisation and financial technology provider. Through collaboration across the private and public sectors, Ant International’s unified techfin platform supports financial institutions and merchants of all sizes to achieve inclusive growth through a comprehensive range of cutting-edge digital payment and financial services solutions. To learn more, please visit https://www.ant-intl.com/en/
About MDEC
The Malaysia Digital Economy Corporation (MDEC) was established in 1996 to spearhead the country’s digital economy. MDEC launched Malaysia Digital (MD), a national strategic initiative aimed at addressing current key challenges in the digital landscape for a robust and agile digital economy. As an agency under the Ministry of Digital, MDEC drives the digital economy through industry development, trade facilitation and policy advocacy. Please visit our website at www.mdec.com.my
About EPOS
EPOS is a leading Point-of-Sale (POS) digital solutions provider, supporting Ant International's mission to empower SME digitalisation. EPOS leverages Antom’s digital capabilities as the organisation’s central hub to serve regional small and medium-sized businesses with integrated O2O digital, payment and banking solutions. For more information about EPOS, please visit https://www.epos.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20260115763131/en/


Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom